![logo](/logos/CRBU.webp)
Caribou Biosciences, Inc.
NASDAQ:CRBU
1.72 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Caribou Biosciences, Inc. |
Symbool | CRBU |
Munteenheid | USD |
Prijs | 1.72 |
Beurswaarde | 155,424,016 |
Dividendpercentage | 0% |
52-weken bereik | 1.5 - 8.33 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Rachel E. Haurwitz Ph.D. |
Website | https://cariboubio.com |
An error occurred while fetching data.
Over Caribou Biosciences, Inc.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)